What Recent “Outstanding Results” in MCL Mean for Practice

“Therapies are improving dramatically” in mantle cell lymphoma (MCL),
according to Michael Wang, MD, professor in the department of
lymphoma/myeloma, division of cancer medicine at the University of Texas
MD Anderson Cancer Center in Houston. Dr. Wang presented updates on
major advances in MCL at the recent Society of Hematologic Oncology
(SOHO) annual meeting. Here, he speaks with Bob Figlin, MD, the Steven
Spielberg family chair in hematology-oncology at Cedars-Sinai Cancer Center
in Los Angeles, about which promising regimens from recent studies are
most appropriate for certain age groups. Dr. Wang and Dr. Figlin also discuss
common challenges when approaching newly diagnosed patients, as well as
how to process the “explosion” of new information in MCL.